Redeye updated its fair value range because of CLS’ reverse share split, where 200 existing shares h...
Sintercast redovisade en positiv start på året och dubblade kassaflödet i kvartalet.
Redeye states that Q1 beat estimates across the board.
Redeye retains its positive view of Sdiptech following a Q1 report that was stronger than our expect...
Redeye’s view on the Q1 report. The organic growth was decent, while the gross margin development co...
Redeye is making some downward adjustments to our financial forecasts, following the Q1 report and a...
Consti’s Q1 net sales beat our estimates slightly while operative profitability missed by only a sma...
Redeye initiates coverage of Precise Biometrics, a global leader in the fingerprint algorithms space...
Redeye takes a positive stance towards Fortnox following an overall solid Q1 report and the negative...
Q1: growth recovery and margin improvements with solid FCF We tweak our '24e sales and adj.
Orders recover from Q4 low, NWC release supports fantastic FCF Some one-offs weigh on profitability,...
Redeye is encouraged to see a slightly higher-than-expected sales development for US CERAMENT G and ...
Orders -5%, sales +1%, adj. EBITA -7% vs. ABGSCe Some negative one-offs in quarter: system changes, ...
Redeye leaves a comment following today’s announcement that Kristina Torfgård has decided to leave h...
Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is movi...
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
Redeye was hoping for a bit more in terms of top-line growth, but we are encouraged by strong gross ...
- Q1: Clean EBITDA NOK -6m - soft compared to our NOK -1m - Targets updated - more achievable - Esti...
Osäkerheten består i det korta, men de strukturella drivkrafterna består Även om affären fortsatte p...
Fortsatt vikande ARR y/y och q/q… Omsättningen i kvartalet uppgick till 37,3 mkr, vilket motsvarar e...
